{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:19Z","timestamp":1792788079290,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GuangDong Basic and Applied Basic Research Foundation","award":["2023A1515140148"],"award-info":[{"award-number":["2023A1515140148"]}]},{"name":"High-level Talent Research Funding Program of the First Dongguan Affiliated Hospital of Guangdong Medical University","award":["GCC2023004"],"award-info":[{"award-number":["GCC2023004"]}]},{"name":"Special Project for Clinical and Basic Sci&Tech Innovation of Guangdong Medical University","award":["GDMULCJC2024098"],"award-info":[{"award-number":["GDMULCJC2024098"]}],"id":[{"id":"https:\/\/ror.org\/04k5rxe29","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Guangdong Medical University Undergraduate Innovation and Entrepreneurship Education Base Project","award":["JDXM2024070F"],"award-info":[{"award-number":["JDXM2024070F"]}],"id":[{"id":"https:\/\/ror.org\/04k5rxe29","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Discipline Construction Project of Guangdong Medical University","award":["2051K20220006"],"award-info":[{"award-number":["2051K20220006"]}],"id":[{"id":"https:\/\/ror.org\/04k5rxe29","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T cell therapy in solid tumors is hampered by dense stromal barriers, rapid functional exhaustion, and limited persistence. Here, we report that low-dose docetaxel acts as an immunomodulatory primer that reprograms CAR T cells to address these barriers. Retrospective analysis of breast cancer patients identifies host lymphocyte reserve as a key determinant of docetaxel treatment benefit, implying an immunological component beyond direct tumor cell killing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sub-cytotoxic docetaxel concentrations were evaluated in primary human T cells and CAR T cells using phenotypic, transcriptional, and functional assays. Secretory profiles and extracellular vesicle cargo were characterized, with efficacy assessed in 3D spheroids and xenograft models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Docetaxel priming induces a \"Metabolic-Cycle Uncoupling\" state, constraining proliferation while enhancing cytotoxic effector potency and memory traits. This reprogramming is associated with upregulation of Rab27-dependent exosome biogenesis, accompanied by shedding of exhaustion markers (PD-1, CD57) and enrichment of cytotoxic ligands (FasL, TRAIL), CAR, and homing receptors (CCR5\/CCR7). Primed CAR T cells exhibit improved antitumor efficacy with associated stromal remodeling and host T cell activation; secreted exosomes contribute to bystander tumor cell killing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings describe a non-genetic pharmacologic priming strategy with potential scalability and compatibility with existing manufacturing processes. This approach demonstrates enhanced CAR T cell performance against solid tumor barriers in preclinical models, highlighting the potential of chemotherapy-immunotherapy synergies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                    <jats:p>Low-dose docetaxel acts as an immunomodulatory primer that reprograms CAR T cells without impairing cellular viability. Sub-cytotoxic concentrations induce cell-cycle arrest with enhanced effector potency and memory traits, redirecting resources toward increased secretory activity. This promotes Rab27-dependent exosome biogenesis, with shedding of exhaustion markers (PD-1, CD57) and enrichment of cytotoxic ligands (FasL, TRAIL), CAR, and homing receptors (CCR5\/CCR7). Primed CAR T cells exhibit improved antitumor efficacy with associated stromal remodeling and host T cell activation; secreted exosomes contribute to bystander tumor cell killing in spheroid and xenograft models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03781-9","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:25:28Z","timestamp":1784107528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-dose docetaxel reprograms CAR T cells for enhanced solid tumor immunity"],"prefix":"10.1186","volume":"45","author":[{"given":"Songshan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangjiu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"3781_CR1","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135. https:\/\/doi.org\/10.1126\/science.aar6711.","journal-title":"Science"},{"key":"3781_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu U, June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol. 2025;43:506\u201315. https:\/\/doi.org\/10.1038\/s41587-024-02446-2.","journal-title":"Nat Biotechnol"},{"key":"3781_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01229-3","author":"ZL Lamplugh","year":"2025","unstructured":"Lamplugh ZL, Wellhausen N, June CH, Fan Y. Microenvironmental regulation of solid tumour resistance to CAR T cell therapy. Nat Rev Immunol. 2025. https:\/\/doi.org\/10.1038\/s41577-025-01229-3.","journal-title":"Nat Rev Immunol"},{"key":"3781_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020. https:\/\/doi.org\/10.1126\/science.aba7365.","journal-title":"Science"},{"key":"3781_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.10.021","author":"S Castelli","year":"2025","unstructured":"Castelli S, Wilson WV, Uslu U, Finck AV, Rommel PC, Assenmacher CA, et al. IL-9 signaling redirects CAR T cell fate toward CD8(+) memory and CD4(+) cycling states, enhancing antitumor efficacy. Immunity. 2025. https:\/\/doi.org\/10.1016\/j.immuni.2025.10.021.","journal-title":"Immunity"},{"key":"3781_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/s0090-4295(99)00451-3","volume":"54","author":"U Vaishampayan","year":"1999","unstructured":"Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology. 1999;54:22\u20139. https:\/\/doi.org\/10.1016\/s0090-4295(99)00451-3.","journal-title":"Urology"},{"key":"3781_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtm.2019.09.007","volume":"16","author":"MS Pampusch","year":"2020","unstructured":"Pampusch MS, Haran KP, Hart GT, Rakasz EG, Rendahl AK, Berger EA, et al. Rapid Transduction and Expansion of Transduced T Cells with Maintenance of Central Memory Populations. Mol Ther Methods Clin Dev. 2020;16:1\u201310. https:\/\/doi.org\/10.1016\/j.omtm.2019.09.007.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3781_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cmpb.2014.12.003","volume":"118","author":"F Piccinini","year":"2015","unstructured":"Piccinini F, Tesei A, Arienti C, Bevilacqua A. Cancer multicellular spheroids: volume assessment from a single 2D projection. Comput Methods Programs Biomed. 2015;118:95\u2013106. https:\/\/doi.org\/10.1016\/j.cmpb.2014.12.003.","journal-title":"Comput Methods Programs Biomed"},{"key":"3781_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmpb.2016.07.024","volume":"135","author":"F Piccinini","year":"2016","unstructured":"Piccinini F, Tesei A, Bevilacqua A. Single-image based methods used for non-invasive volume estimation of cancer spheroids: a practical assessing approach based on entry-level equipment. Comput Methods Programs Biomed. 2016;135:51\u201360. https:\/\/doi.org\/10.1016\/j.cmpb.2016.07.024.","journal-title":"Comput Methods Programs Biomed"},{"key":"3781_CR10","doi-asserted-by":"publisher","unstructured":"Th\u00e9ry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006:Chapter 3:Unit 3.22. https:\/\/doi.org\/10.1002\/0471143030.cb0322s30.","DOI":"10.1002\/0471143030.cb0322s30"},{"key":"3781_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nm.2753","volume":"18","author":"H Peinado","year":"2012","unstructured":"Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883\u201391. https:\/\/doi.org\/10.1038\/nm.2753.","journal-title":"Nat Med"},{"key":"3781_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382\u20136. https:\/\/doi.org\/10.1038\/s41586-018-0392-8.","journal-title":"Nature"},{"key":"3781_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ccr.2014.07.026","volume":"26","author":"Z Xiang","year":"2014","unstructured":"Xiang Z, Liu Y, Zheng J, Liu M, Lv A, Gao Y, et al. Targeted activation of human Vgamma9Vdelta2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. Cancer Cell. 2014;26:565\u201376. https:\/\/doi.org\/10.1016\/j.ccr.2014.07.026.","journal-title":"Cancer Cell"},{"key":"3781_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59\u201373. https:\/\/doi.org\/10.1038\/nri2216.","journal-title":"Nat Rev Immunol"},{"key":"3781_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28:690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012.","journal-title":"Cancer Cell"},{"key":"3781_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(17)30904-X.","journal-title":"Lancet Oncol"},{"key":"3781_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.ccell.2023.05.009","volume":"41","author":"C Vennin","year":"2023","unstructured":"Vennin C, Cattaneo CM, Bosch L, Vegna S, Ma X, Damstra HGJ, et al. Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity. Cancer Cell. 2023;41:1170-1185 e1112. https:\/\/doi.org\/10.1016\/j.ccell.2023.05.009.","journal-title":"Cancer Cell"},{"key":"3781_CR18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41423-024-01228-9","volume":"21","author":"R Zheng","year":"2024","unstructured":"Zheng R, Shen K, Liang S, Lyu Y, Zhang S, Dong H, et al. Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors. Cell Mol Immunol. 2024;21:1491\u2013504. https:\/\/doi.org\/10.1038\/s41423-024-01228-9.","journal-title":"Cell Mol Immunol"},{"key":"3781_CR19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290\u20137. https:\/\/doi.org\/10.1038\/nm.2446.","journal-title":"Nat Med"},{"key":"3781_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau0135","author":"SK Vodnala","year":"2019","unstructured":"Vodnala SK, Eil R, Kishton RJ, Sukumar M, Yamamoto TN, Ha NH, et al. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science. 2019. https:\/\/doi.org\/10.1126\/science.aau0135.","journal-title":"Science"},{"key":"3781_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s42003-020-1027-9","volume":"3","author":"PJ Ahl","year":"2020","unstructured":"Ahl PJ, Hopkins RA, Xiang WW, Au B, Kaliaperumal N, Fairhurst AM, et al. Met-Flow, a strategy for single-cell metabolic analysis highlights dynamic changes in immune subpopulations. Commun Biol. 2020;3:305. https:\/\/doi.org\/10.1038\/s42003-020-1027-9.","journal-title":"Commun Biol"},{"key":"3781_CR22","doi-asserted-by":"publisher","first-page":"103518","DOI":"10.1016\/j.xpro.2024.103518","volume":"6","author":"K Miki","year":"2025","unstructured":"Miki K, Yagi M, Igami K, Kittaka H, Tani A, Horiuchi N, et al. Live-cell metabolic analyzer protocol for measuring glucose and lactate metabolic changes in human cells. STAR Protoc. 2025;6:103518. https:\/\/doi.org\/10.1016\/j.xpro.2024.103518.","journal-title":"STAR Protoc"},{"key":"3781_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21:524\u20139. https:\/\/doi.org\/10.1038\/nm.3833.","journal-title":"Nat Med"},{"key":"3781_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.1254536","volume":"346","author":"JM Schenkel","year":"2014","unstructured":"Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D. T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science. 2014;346:98\u2013101. https:\/\/doi.org\/10.1126\/science.1254536.","journal-title":"Science"},{"key":"3781_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","volume":"121","author":"N Cieri","year":"2013","unstructured":"Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121:573\u201384. https:\/\/doi.org\/10.1182\/blood-2012-05-431718.","journal-title":"Blood"},{"key":"3781_CR26","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177:414-427 e413. https:\/\/doi.org\/10.1016\/j.cell.2019.02.016.","journal-title":"Cell"},{"key":"3781_CR27","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Li CW, Chan LC, Wei Y, Hsu JM, Xia W, et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018;28:862\u20134. https:\/\/doi.org\/10.1038\/s41422-018-0060-4.","journal-title":"Cell Res"},{"key":"3781_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.trecan.2020.03.002","volume":"6","author":"SM Morrissey","year":"2020","unstructured":"Morrissey SM, Yan J. Exosomal PD-L1: roles in tumor progression and immunotherapy. Trends Cancer. 2020;6:550\u20138. https:\/\/doi.org\/10.1016\/j.trecan.2020.03.002.","journal-title":"Trends Cancer"},{"key":"3781_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20:531\u201350. https:\/\/doi.org\/10.1038\/s41573-021-00189-2.","journal-title":"Nat Rev Drug Discov"},{"key":"3781_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","volume":"2","author":"L Labanieh","year":"2018","unstructured":"Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018;2:377\u201391. https:\/\/doi.org\/10.1038\/s41551-018-0235-9.","journal-title":"Nat Biomed Eng"},{"key":"3781_CR31","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.ymthe.2025.02.012","volume":"33","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Zhang J, Mu W, Ye S, Cheng J, Zhu L, et al. Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Mol Ther. 2025;33:1535\u201351. https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.012.","journal-title":"Mol Ther"},{"key":"3781_CR32","doi-asserted-by":"publisher","unstructured":"Reiner SL. Immune regeneration: implications for cancer immunotherapy and beyond. J Clin Invest. 2025;135. https:\/\/doi.org\/10.1172\/JCI192731.","DOI":"10.1172\/JCI192731"},{"key":"3781_CR33","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1158\/1078-0432.CCR-21-1442","volume":"28","author":"L Kester","year":"2022","unstructured":"Kester L, Seinstra D, van Rossum AGJ, Vennin C, Hoogstraat M, van der Velden D, et al. Differential survival and therapy benefit of patients with breast cancer are characterized by distinct epithelial and immune cell microenvironments. Clin Cancer Res. 2022;28:960\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1442.","journal-title":"Clin Cancer Res"},{"key":"3781_CR34","doi-asserted-by":"publisher","first-page":"100742","DOI":"10.1016\/j.drup.2020.100742","volume":"54","author":"L Mosca","year":"2021","unstructured":"Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54:100742. https:\/\/doi.org\/10.1016\/j.drup.2020.100742.","journal-title":"Drug Resist Updat"},{"key":"3781_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13046-016-0433-9","volume":"35","author":"R Visconti","year":"2016","unstructured":"Visconti R, Della Monica R, Grieco D. Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. J Exp Clin Cancer Res. 2016;35:153. https:\/\/doi.org\/10.1186\/s13046-016-0433-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"3781_CR36","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.7150\/thno.73152","volume":"12","author":"Z Ma","year":"2022","unstructured":"Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R, et al. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics. 2022;12:4965\u201379. https:\/\/doi.org\/10.7150\/thno.73152.","journal-title":"Theranostics"},{"key":"3781_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41590-025-02407-0","volume":"27","author":"FJ van Haften","year":"2026","unstructured":"van Haften FJ, van der Sluis TC, Hepp HS, Mulling N, Nadafi R, Sampadi B, et al. Cell cycle arrest enhances CD8(+) T cell effector function by potentiating glucose metabolism and IL-2 signaling. Nat Immunol. 2026;27:463\u201375. https:\/\/doi.org\/10.1038\/s41590-025-02407-0.","journal-title":"Nat Immunol"},{"key":"3781_CR38","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s1074-7613(02)00323-0","volume":"16","author":"KA Frauwirth","year":"2002","unstructured":"Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16:769\u201377. https:\/\/doi.org\/10.1016\/s1074-7613(02)00323-0.","journal-title":"Immunity"},{"key":"3781_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ncb2000","volume":"12","author":"M Ostrowski","year":"2010","unstructured":"Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12:19\u201330. https:\/\/doi.org\/10.1038\/ncb2000. sup pp 11-13.","journal-title":"Nat Cell Biol."},{"key":"3781_CR40","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","volume":"10","author":"W Fu","year":"2019","unstructured":"Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10:4355. https:\/\/doi.org\/10.1038\/s41467-019-12321-3.","journal-title":"Nat Commun"},{"key":"3781_CR41","doi-asserted-by":"publisher","unstructured":"Wang X, Xiang Z, Liu Y, Huang C, Pei Y, Wang X, Zhi H, Wong WH, Wei H, Ng IO, et al. Exosomes derived from Vdelta2-T cells control Epstein-Barr virus-associated tumors and induce T cell antitumor immunity. Sci Transl Med. 2020;12. https:\/\/doi.org\/10.1126\/scitranslmed.aaz3426.","DOI":"10.1126\/scitranslmed.aaz3426"},{"key":"3781_CR42","doi-asserted-by":"publisher","DOI":"10.3402\/jev.v3.24641","author":"LA Mulcahy","year":"2014","unstructured":"Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014. https:\/\/doi.org\/10.3402\/jev.v3.24641.","journal-title":"J Extracell Vesicles"},{"key":"3781_CR43","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.7150\/thno.52570","volume":"11","author":"Y Liang","year":"2021","unstructured":"Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11:3183\u201395. https:\/\/doi.org\/10.7150\/thno.52570.","journal-title":"Theranostics"},{"key":"3781_CR44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","volume":"527","author":"A Hoshino","year":"2015","unstructured":"Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329\u201335. https:\/\/doi.org\/10.1038\/nature15756.","journal-title":"Nature"},{"key":"3781_CR45","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","volume":"184","author":"LR Johnson","year":"2021","unstructured":"Johnson LR, Lee DY, Eacret JS, Ye D, June CH, Minn AJ. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell. 2021;184:4981-4995 e4914. https:\/\/doi.org\/10.1016\/j.cell.2021.08.004.","journal-title":"Cell"},{"key":"3781_CR46","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582\u201398. https:\/\/doi.org\/10.1038\/nrc.2016.73.","journal-title":"Nat Rev Cancer"},{"key":"3781_CR47","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","volume":"9","author":"MA Lakins","year":"2018","unstructured":"Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 (+) T cells to protect tumour cells. Nat Commun. 2018;9:948. https:\/\/doi.org\/10.1038\/s41467-018-03347-0.","journal-title":"Nat Commun"},{"key":"3781_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.12.025","author":"H Wang","year":"2025","unstructured":"Wang H, Liu S, Sinha P, Liu F, Zhang X, Guo Y, et al. DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity. Mol Ther. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.025.","journal-title":"Mol Ther"},{"key":"3781_CR49","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654\u20139. https:\/\/doi.org\/10.1038\/ncb1596.","journal-title":"Nat Cell Biol"},{"key":"3781_CR50","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ncomms1285","volume":"2","author":"M Mittelbrunn","year":"2011","unstructured":"Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, Gonzalez MA, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2011;2:282. https:\/\/doi.org\/10.1038\/ncomms1285.","journal-title":"Nat Commun"},{"key":"3781_CR51","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559\u201372. https:\/\/doi.org\/10.1038\/nri.2017.49.","journal-title":"Nat Rev Immunol"},{"key":"3781_CR52","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","volume":"401","author":"F Sallusto","year":"1999","unstructured":"Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708\u201312. https:\/\/doi.org\/10.1038\/44385.","journal-title":"Nature"},{"key":"3781_CR53","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","volume":"14","author":"CT Garnett","year":"2008","unstructured":"Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14:3536\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4025.","journal-title":"Clin Cancer Res"},{"key":"3781_CR54","doi-asserted-by":"publisher","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367. https:\/\/doi.org\/10.1126\/science.aau6977.","DOI":"10.1126\/science.aau6977"},{"key":"3781_CR55","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Thery","year":"2018","unstructured":"Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750. https:\/\/doi.org\/10.1080\/20013078.2018.1535750.","journal-title":"J Extracell Vesicles"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03781-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03781-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03781-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:22:39Z","timestamp":1789629759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03781-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3781"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03781-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The clinical retrospective study was approved by the Medical Ethics Committee of The People's Hospital of Guangxi Zhuang Autonomous Region, under approval number KY-ZC-2023\u2013003. All human specimen studies were approved by the Medical Ethics Committee of The First Dongguan Affiliated Hospital of Guangdong Medical University, under approval number SLYJ202504007, and written informed consent was obtained from all participants. All animal experiments were approved by the Experimental Animal Ethics Committee of Guangdong Medical University (Approval number: GDMU-2025\u2013000049).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"198"}}